Oral vs. injectable semaglutide: daily pill or weekly shot?

Every product here contains semaglutide, a GLP-1 receptor agonist. It slows stomach emptying, turns down appetite signals and helps the pancreas release insulin when glucose is high. The difference is how the drug gets into the blood.

Injections go under the skin once a week, so no digestion is involved. Tablets have to get past the stomach first. They are made with an absorption enhancer called SNAC, and the label explains that absorption happens mainly in the stomach. That is why tablets come with a routine: take on waking with up to 4 ounces of water, then nothing else for at least 30 minutes. It is also why tablet doses are larger in milligrams than weekly shots.

The approved products split by use:

• Weight management: Wegovy injection (2.4 mg weekly, or 7.2 mg as Wegovy HD) and the Wegovy pill (25 mg daily).
• Type 2 diabetes: Ozempic injection (up to 2 mg weekly) and the Ozempic pill (up to 9 mg daily), which replaced Rybelsus in the US in 2026.

Compounded versions of both routes are sold too. They are not FDA-approved.

The approved weight-management doses have not been tested against each other in a single trial. Two placebo-controlled trials give the clearest side-by-side view.

• Tablet — OASIS 4 (NEJM, 2025) randomized 307 adults with obesity or overweight to oral semaglutide 25 mg or placebo. Mean weight change at 64 weeks was −13.6% versus −2.2%, counting everyone. Novo Nordisk reports 16.6% among people who took the tablet as directed.
• Injection — STEP 1 (NEJM, 2021) reported −14.9% at 68 weeks on 2.4 mg weekly, against −2.4% on placebo.

A 2026 modeling analysis in Diabetes, Obesity and Metabolism found that 82% of OASIS 4 tablet users reached semaglutide blood levels within the range seen with the 2.4 mg injection in STEP 1. That helps explain why the results sit close together.

The injection has the higher ceiling. STEP UP (Lancet Diabetes & Endocrinology, 2025) reported −18.7% at 72 weeks on 7.2 mg weekly. No tablet dose has comparable data.

For diabetes, SUSTAIN FORTE showed HbA1c falling 2.2 points on the 2 mg injection over 40 weeks. PIONEER 4 showed a 1.2-point fall on the 14 mg tablet at 26 weeks. Different people and time frames make that a rough comparison only.

Both routes share one side-effect profile, since the same molecule ends up in the bloodstream. Nausea, vomiting, diarrhea and constipation lead the list and cluster around dose increases.

The Wegovy prescribing information reports nausea in 44% of adults on the 2.4 mg injection. The prescribing information for Rybelsus and the Ozempic pill reports nausea in 20% at 14 mg. Those numbers come from different trials and doses, so they do not show that one route is gentler.

A few issues are route-specific. The tablet's absorption depends on the fasting routine. In a label interaction study, the tablet also raised levothyroxine exposure by 33%. Both routes slow gastric emptying, which can change how other oral drugs absorb.

The Wegovy label reports dysesthesia, meaning tingling, burning or sensitive skin, with both the injection and the tablet, and the rate rises with dose. Serious shared risks include pancreatitis, gallbladder disease, kidney injury from dehydration and diabetic eye complications. Both routes carry the boxed warning on thyroid C-cell tumors in rodents.

Choose the tablet if needles are a real barrier, your mornings follow a fixed pattern, and your other morning pills can wait 30 minutes.

Choose the injection if your mornings vary, you take time-sensitive morning medicines, or you would rather act once a week. The injection is also the only way to reach Wegovy HD's 7.2 mg dose.

Switching routes follows the Wegovy label. From the 2.4 mg injection to the 25 mg tablet, start the tablet one week after the last shot. From the 25 mg tablet to the injection, start 2.4 mg the day after the last tablet. If 25 mg tablets are not tolerated, the label suggests considering the 1.7 mg injection.

Neither route suits anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Severe gastroparesis is another reason to avoid both.

Compounded semaglutide, oral or injected, is not FDA-approved. Its strength and absorption depend on the pharmacy's formulation rather than a tested label. If you use one, ask the pharmacy exactly how to take it and what strength it contains.